A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Phase 3

Terminated

• Conditions: Hyperlipidemia; Dyslipidemia

• Registration Number: NCT00267267
• Lead Sponsor: Pfizer

Brief Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to see how the different treatments compare to one another.

Detailed Description

For additional information please call: 1-800-718-1021

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2005-12-19
• Study First Submitted QC: 2005-12-19
• Study First Posted: 2005-12-20
• Study Start: 2006-01
• Status Verified: 2006-12
• Study Completion: 2007-01
• Last Update Submitted: 2007-12-06
• Last Update Posted: 2007-12-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1784

Inclusion Criteria

• Specific LDL-C levels based on CHD risk after a six-week washout period.

Read More

Exclusion Criteria

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
• Subjects requiring systemic steroids
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Percent change in LDL-C and HDL-C from baseline, after six weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
Changes in other lipid parameters and other biomarkers.

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Spokane, Washington, United States